Surrozen Inc

TCG Crossover GP II, LLC’s steady buying of Surrozen shares signals confidence despite weak earnings—watch for clinical milestones that could unlock upside.

Surrozen’s new 31% stake by TCG Crossover signals a bullish shift—insider buys hint at value and potential upside as the biotech nears commercial launch.

Li Yang’s massive stock‑option and RSU exercise signals insider confidence and may boost Surrozen’s share price, hinting at a short‑term rally for investors.

Column Group III GP’s latest $19.89 buy of 15,100 Surrozen shares shows long‑term confidence in its biotech pipeline, hinting at upside if clinical milestones hit.